Massimo Iavarone

The authors in today’s #readoftheweek📚 discuss how patients with #ALD and #MASLD are underrepresented in #HCC risk model development studies.

Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...

#LiverSky @jhepatology.bsky.social

22.01.2025 14:01 — 👍 7    🔁 1    💬 0    📌 0

🆕 Treatment of refractory #ascites: TIPS, tunneled peritoneal catheter (PeCa), or ascites pump?

🥇 TIPS: lowest incidence of complications
🦠 PeCa: peritonitis & device explantations 📈

👥 Sarah Schütte et al in Hepatology Communications
🔗 bit.ly/42k8too

#liversky #medsky #cirrhosis

21.01.2025 11:06 — 👍 6    🔁 4    💬 1    📌 0

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft sa...

#atezolizumab plus #bevacizumab prior #liver #transplantation for #HCC - JHEP Reports www.jhep-reports.eu/article/S258...
🔹 82% downstaged to Milan criteria
🔹 94% radiological response (59% CR)
🔹 88% pathological response
🔹 No graft loss or severe rejection
A potential game-changer!

22.01.2025 17:46 — 👍 1    🔁 0    💬 0    📌 0